Cite
HARVARD Citation
Yu, E. et al. (n.d.). 345 Phase 3 study of combination pembrolizumab + olaparib therapy versus enzalutamide/abiraterone in metastatic castration-resistant prostate cancer (mCRPC) after progression on chemotherapy (KEYLYNK-010). Journal for immunotherapy of cancer. p. A370. [Online].